168 results
S-8
EX-4.2
DRRX
Durect Corp
18 May 01
Registration of securities for employees
12:00am
Termination of Employment Due to Death, Disability, or
------------------------------------------------------
Retirement. In the event … the employment of a Participant is terminated by reason
- ----------
of death, Disability or Retirement, the rights under any then outstanding Option
8-K
EX-99.1
DRRX
Durect Corp
1 Jul 20
Other Events
9:01am
and kidney injury are risk factors for poor outcomes in COVID-19 patients
The risk of death from multi-organ failure is present in both patients … patients.
“Unfortunately, acute liver or kidney injury is associated with a significantly increased risk of death in hospitalized COVID-19 patients
8-K
EX-99.1
DRRX
Durect Corp
16 May 23
Regulation FD Disclosure
12:08pm
Multiple causes of death including sepsis and liver failure Methods of assessing AH severity Current therapeutic options 12
Case Presentation – A Sample … Liver Fatty Liver Increasing Fibrosis Cirrhosis Decompensated Cirrhosis Death Liver Transplant Alcohol Alcohol Alcohol Steatohepatitis Severe AH Mild
S-1
EX-10.5
DRRX
Durect Corp
20 Apr 00
IPO registration
12:00am
the unexercised portion of the Option shall revert to the Plan.
(d) Death of Optionee. In the event of the death of an Optionee … : (A)
-----------------
during the term of the Option who is, at the time of his or her death, a
Director of the Company and who shall have been
8-K
EX-99.1
DRRX
Durect Corp
9 Mar 21
DURECT Corporation Announces Publication of DUR-928’s Mechanism of Action
9:57am
activities, including those associated with cell death, stress response, and lipid biosynthesis. These modulations may lead to improved cell survival … , severe inflammation and liver cell death, with an average 90-day mortality rate of 29%,” said Norman Sussman, MD, FAASLD, Chief Medical Officer
8-K
EX-99.2
f9j 0pjb2k6
7 Nov 23
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
4:10pm
S-1
EX-10.3
glhnilpjl 4vw7z0
20 Apr 00
IPO registration
12:00am
S-1
EX-10.4
mmmosuislrzi0e3pc3k
20 Apr 00
IPO registration
12:00am
8-K
EX-99.1
5nbkttb 3ez5pc5
7 Jun 23
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
9:00am
8-K
EX-10.1
9yd0rv3acuv5s
20 Jun 18
Departure of Directors or Certain Officers
4:35pm
8-K
EX-10.1
nxorqm8fb0qg aytohy
20 Jun 19
Departure of Directors or Certain Officers
4:42pm
8-K
EX-10.1
5bt23
18 Jun 20
Departure of Directors or Certain Officers
4:30pm
PRE 14A
EX-2
ragwtarn42c84yhlv
15 Apr 10
Preliminary proxy
12:00am
8-K
EX-10.1
jjohwlx7qq jh0ugjq
16 Jun 22
Departure of Directors or Certain Officers
5:01pm
8-K
EX-10.1
zlcsnkbah3w0jis9u
22 Jun 23
Departure of Directors or Certain Officers
4:30pm
S-1
EX-10.2
ndilox8
20 Apr 00
IPO registration
12:00am